Monopar Therapeutics (MNPR) reported a third-quarter 2026 net loss of $6.2 million, or $0.72 per share, compared with a $3.4 million net loss, or $0.48 per share, in the prior-year quarter.
The company ended September 30, 2026, with $129.4 million in cash, cash equivalents and investments and said it expects current funds to support operations through at least March 31, 2028. Monopar said it is on track to complete the rolling FDA New Drug Application submission for ALXN1840 within the next several weeks.
- Third-quarter R&D expenses were $4,436,543, versus $2,589,749 a year earlier.
- Third-quarter G&A expenses were $3,031,302, versus $1,503,326 a year earlier.
- Interest income totaled $1,271,370, compared with $655,473 in the third quarter of 2025.
- Monopar presented Phase 3 FoCus study baseline findings for ALXN1840 in Wilson disease at AASLD The Liver Meeting 2026.
$MNPR Insider Trading Activity
$MNPR insiders have traded $MNPR stock on the open market 25 times in the past 6 months. Of those trades, 0 have been purchases and 25 have been sales.
Here’s a breakdown of recent trading of $MNPR stock by insiders over the last 6 months:
- CHANDLER ROBINSON (Chief Executive Officer) has made 0 purchases and 4 sales selling 29,056 shares for an estimated $2,556,850.
- KIM R TSUCHIMOTO has made 0 purchases and 10 sales selling 8,180 shares for an estimated $745,628.
- CHRISTOPHER M STARR has made 0 purchases and 3 sales selling 8,400 shares for an estimated $659,386.
- RAYMOND ANDERSON has made 0 purchases and 7 sales selling 6,284 shares for an estimated $565,935.
- PATRICE RIOUX sold 1 shares for an estimated $111
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MNPR Hedge Fund Activity
We have seen 67 institutional investors add shares of $MNPR stock to their portfolio, and 36 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIO CAPITAL MANAGEMENT, LLC removed 173,506 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $16,064,920
- ORBIMED ADVISORS LLC added 157,423 shares (+inf%) to their portfolio in Q2 2026, for an estimated $14,575,795
- DEERFIELD MANAGEMENT COMPANY, L.P. added 153,187 shares (+89.8%) to their portfolio in Q2 2026, for an estimated $14,183,584
- STATE STREET CORP added 137,220 shares (+148.3%) to their portfolio in Q3 2026, for an estimated $10,932,317
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 100,000 shares (-32.3%) from their portfolio in Q2 2026, for an estimated $9,259,000
- TCG CROSSOVER MANAGEMENT, LLC added 71,224 shares (+53.9%) to their portfolio in Q2 2026, for an estimated $6,594,630
- WALLEYE CAPITAL LLC removed 63,119 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $5,844,188
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
